Ophthalmology and Visual Sciences

ABID Study

Posted on

Study:   Age-Related Macular Degeneration Benchmark Imaging Dataset – University of Wisconsin-Madison (ABID – UW)

Principal Investigator: Amitha Domalpally, MD, PhD

Clinical Collaborator: Barbara Blodi, MD

This is a prospective, cross-sectional, multi-center, observational study to collect and develop a meticulously curated and diverse AMD benchmark dataset, featuring reference standard level 1 classification and comprehensive annotation of images.

Study procedures include: collecting demographics (age, sex, ethnicity, race), smoking history, family history of AMD, and height/weight; collecting or measuring visual acuity (BCVA); assessing AMD classification (Beckman scale); and undergoing one retinal imaging session (color fundus photography (pre and post dilation) and spectral domain-optical coherence tomography) of both eyes

Inclusion Criteria:

  1. Participants greater than or equal to 50 years of age at time of signing Informed Consent Form
  2. Willing to comply with all study procedures and sign the Informed Consent Form (ICF)
  3. Individuals with normal healthy eyes or diagnosed with any stage of Age-Related Macular Degeneration (treatment naïve patients with early, intermediate, or late AMD). The diagnosis and eligibility review will be confirmed by Central Reading Center.

Exclusion Criteria:

  1. Therapeutic treatment for any type of AMD, in either eye. Supplements, such as AREDS2 formula, are allowed.
  2. Unable to acquire adequate quality images, as evaluated by the Central Reading Center
  3. Severe vision loss requiring urgent surgery
  4. Contraindicated for acquiring retinal images due to narrow anterior chamber angles or hypersensitivity to light
  5. A systemic or ocular condition that in the opinion of the Investigator would preclude participation in the study
  6. Unwilling to sign informed consent form
  7. Currently or previously enrolled in an interventional AMD clinical trial

Contact Bonnie Verges (608-265-5292) or Denise Krolnik (608-265-2574) with questions.

For more information about this study, visit clinicaltrials.gov